Skip to main content
Premium Trial:

Request an Annual Quote

CombiMatrix Execs to Participate in $5M Stock Purchase

NEW YORK (GenomeWeb News) - Acacia Research said yesterday that it has received commitments for the purchase of $5 million in Acacia Research-CombiMatrix common stock and warrants through a direct offering that includes several CombiMatrix executives. 
 
Acacia plans to sell 6.8 million units at $.738 per share to "a select group of investors" including CombiMatrix President and CEO Amit Kumar and company directors Tom Akin and John Abeles.
 
The company said each share will consist of a share of Acacia-CombiMatrix common stock and a five-year warrant to buy 1.5 shares at a price of $.55 per share.
 
Kumar said in a statement that the financing will strengthen CombiMatrix's balance sheet as it prepares to split from parent company Acacia, a plan that it announced in January.
 
The financing also “provides additional capital to fund our expansion in the molecular diagnostics market," Kumar said.

The Scan

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.

DNA Storage Method Taps Into Gene Editing Technology

With a dual-plasmid system informed by gene editing, researchers re-wrote DNA sequences in E. coli to store Charles Dickens prose over hundreds of generations, as they recount in Science Advances.

Researchers Model Microbiome Dynamics in Effort to Understand Chronic Human Conditions

Investigators demonstrate in PLOS Computational Biology a computational method for following microbiome dynamics in the absence of longitudinally collected samples.

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.